Related Experiment Video
Updated: May 17, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Guideline for hereditary angioedema (HAE) 2010 by the Japanese Association for Complement Research - secondary
Takahiko Horiuchi1, Hiroyuki Ohi, Isao Ohsawa
1Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan. horiuchi@intmed1.med.kyushu−u.ac.jp
Insights
This guideline helps clinicians accurately diagnose and promptly treat hereditary angioedema (HAE) in Japan. It is a 2010 version, awaiting updates for medical advancements.
Area of Science:
- Immunology
- Clinical Medicine
Background:
- Hereditary angioedema (HAE) is a rare genetic disorder.
- Accurate diagnosis and timely treatment are crucial for HAE patients.
Purpose of the Study:
- To provide a clinical guideline for HAE diagnosis and treatment in Japan.
- To support clinicians in managing HAE patients effectively.
Main Methods:
- Guideline development by the Japanese Association for Complement Research.
- Targeting clinicians for practical application.
Main Results:
- Established diagnostic criteria for HAE.
- Recommended treatment protocols for HAE management.
Conclusions:
- The guideline aims to improve HAE patient outcomes in Japan.
- This 2010 version requires updates based on future medical advancements.
Abstract:
This guideline was provided by the Japanese Association for Complement Research targeting clinicians for making an accurate diagnosis of hereditary angioedema (HAE), and for prompt treatment of the HAE patient in Japan. This is a 2010 year version and will be updated according to any pertinent medical advancements.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Rheumatic Heart Disease IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins